PMC9520193_01
Intestinal ulcers in four patients with intestinal Behcet's Syndrome before tofacitinib administration: (A) Ileocecal ulcer in case 1; (B) Ileum ulcer in case 2; (C) Ileocecal ulcer in case 3; (D) Ileocecal ulcer in case 4.
fimmu-13-981502-g001.jpg
PMC9520193_04_fimmu-13-981502-g001.jpg
f1
On August 17, 2021, enteroscopy showed that an ulcer with a size of about 4.0 cm x 1.2 cm in the ring 2/3 cavity was found near the ileocecal valve, which was characterized by white scar in the local mucosa, congestion and edema in the surrounding mucosa ( Figure 1D ).
Efficacy of tofacitinib for patients with intestinal Behcet's syndrome (red: case 1; blue: case 2; green: case 3; brown: case 4). (A) Changes in erythrocyte sedimentation rate (ESR); (B) Changes in C-reactive protein (CRP); (C) Changes in disease activity index of intestinal Behcet's disease (DAIBD); (D) Changes in prednisone dosage, during tofacitinib treatment.
fimmu-13-981502-g002.jpg
PMC9520193_04_fimmu-13-981502-g002.jpg
f2
In December 2021, enteroscopy revealed that the ileocecal ulcer had healed, and the patient's DAIBD score, ESR, and CRP levels were normal ( Figure 2 ).
PMC9520193_02
Intestinal ulcers in four patients with intestinal Behcet's Syndrome before tofacitinib administration: (A) Ileocecal ulcer in case 1; (B) Ileum ulcer in case 2; (C) Ileocecal ulcer in case 3; (D) Ileocecal ulcer in case 4.
fimmu-13-981502-g001.jpg
PMC9520193_04_fimmu-13-981502-g001.jpg
f1
On August 17, 2021, enteroscopy showed that an ulcer with a size of about 4.0 cm x 1.2 cm in the ring 2/3 cavity was found near the ileocecal valve, which was characterized by white scar in the local mucosa, congestion and edema in the surrounding mucosa ( Figure 1D ).
Efficacy of tofacitinib for patients with intestinal Behcet's syndrome (red: case 1; blue: case 2; green: case 3; brown: case 4). (A) Changes in erythrocyte sedimentation rate (ESR); (B) Changes in C-reactive protein (CRP); (C) Changes in disease activity index of intestinal Behcet's disease (DAIBD); (D) Changes in prednisone dosage, during tofacitinib treatment.
fimmu-13-981502-g002.jpg
PMC9520193_04_fimmu-13-981502-g002.jpg
f2
In December 2021, enteroscopy revealed that the ileocecal ulcer had healed, and the patient's DAIBD score, ESR, and CRP levels were normal ( Figure 2 ).
PMC9520193_03
Intestinal ulcers in four patients with intestinal Behcet's Syndrome before tofacitinib administration: (A) Ileocecal ulcer in case 1; (B) Ileum ulcer in case 2; (C) Ileocecal ulcer in case 3; (D) Ileocecal ulcer in case 4.
fimmu-13-981502-g001.jpg
PMC9520193_04_fimmu-13-981502-g001.jpg
f1
On August 17, 2021, enteroscopy showed that an ulcer with a size of about 4.0 cm x 1.2 cm in the ring 2/3 cavity was found near the ileocecal valve, which was characterized by white scar in the local mucosa, congestion and edema in the surrounding mucosa ( Figure 1D ).
Efficacy of tofacitinib for patients with intestinal Behcet's syndrome (red: case 1; blue: case 2; green: case 3; brown: case 4). (A) Changes in erythrocyte sedimentation rate (ESR); (B) Changes in C-reactive protein (CRP); (C) Changes in disease activity index of intestinal Behcet's disease (DAIBD); (D) Changes in prednisone dosage, during tofacitinib treatment.
fimmu-13-981502-g002.jpg
PMC9520193_04_fimmu-13-981502-g002.jpg
f2
In December 2021, enteroscopy revealed that the ileocecal ulcer had healed, and the patient's DAIBD score, ESR, and CRP levels were normal ( Figure 2 ).
PMC9520193_04
Intestinal ulcers in four patients with intestinal Behcet's Syndrome before tofacitinib administration: (A) Ileocecal ulcer in case 1; (B) Ileum ulcer in case 2; (C) Ileocecal ulcer in case 3; (D) Ileocecal ulcer in case 4.
fimmu-13-981502-g001.jpg
PMC9520193_04_fimmu-13-981502-g001.jpg
f1
On August 17, 2021, enteroscopy showed that an ulcer with a size of about 4.0 cm x 1.2 cm in the ring 2/3 cavity was found near the ileocecal valve, which was characterized by white scar in the local mucosa, congestion and edema in the surrounding mucosa ( Figure 1D ).
Efficacy of tofacitinib for patients with intestinal Behcet's syndrome (red: case 1; blue: case 2; green: case 3; brown: case 4). (A) Changes in erythrocyte sedimentation rate (ESR); (B) Changes in C-reactive protein (CRP); (C) Changes in disease activity index of intestinal Behcet's disease (DAIBD); (D) Changes in prednisone dosage, during tofacitinib treatment.
fimmu-13-981502-g002.jpg
PMC9520193_04_fimmu-13-981502-g002.jpg
f2
In December 2021, enteroscopy revealed that the ileocecal ulcer had healed, and the patient's DAIBD score, ESR, and CRP levels were normal ( Figure 2 ).